Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

Kevin R. Kelly(Keck Hospital of USC), Jennifer S. Carew(University of Arizona), Pietro Taverna, Kelli Oberheu(The University of Texas at San Antonio Health Science Center), Claudia M. Espitia(The University of Texas System), Gavin Choy(SuperGen (United States)), Francis J. Giles(National University of Ireland), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Steffan T. Nawrocki(University of Arizona), Ernest Medina(The University of Texas at San Antonio Health Science Center)
Blood
November 19, 2010
10.1182/blood.v116.21.3253.3253
Cited by 0

Related Papers

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
|Blood|2006|691
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485